HMG- CoA- reduktasehæmmere, der primært metaboliseres af CYP3A4 (f. eks. lovastatin og simvastatin), forventes at få en markant stigning af plasmakoncentrationen ved samtidig administration med Telzir og ritonavir.
HMG-CoA reductase inhibitors which are highly dependent on CYP3A4 for metabolism, such as lovastatin and simvastatin, are expected to have markedly increased plasma concentrations when co-administered with Telzir with ritonavir.